Immix Biopharma (IMMX) Projected to Release Earnings on Friday

Key Points

• Immix Biopharma is expected to report Q3 2026 earnings on November 6, with analysts forecasting a loss of $0.18 per share. Its earnings conference call is scheduled for November 10 at 4:00 p.m. ET.
• The company reported a larger-than-expected loss in the prior quarter, posting EPS of $(0.18) versus the consensus estimate of $(0.17). Analysts project full-year and next-year losses of $(0.76) and $(0.86) per share, respectively.
• Analyst sentiment remains mostly positive, with eight Buy ratings and one Sell rating, producing a “Moderate Buy” consensus and a $23.86 average price target. Immix’s lead candidate is NXC-201, an investigational CAR-T therapy targeting certain blood cancers.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) is anticipated to issue its Q3 2026 resultson Friday, November 6th. Analysts expect Immix Biopharma to announce earnings of ($0.18) per share for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

Immix Biopharma (NASDAQ:IMMX - Get Free Report) last released its earnings results on Friday, August 7th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.01). On average, analysts expect Immix Biopharma to post ($0.76) EPS for the current fiscal year and ($0.86) EPS for the next fiscal year.

Immix Biopharma Stock Performance

Shares of NASDAQ:IMMX opened at $7.98 on Friday. The stock has a market capitalization of $570.89 million, a price-to-earnings ratio of -9.07 and a beta of 0.24. Immix Biopharma has a 1-year low of $2.85 and a 1-year high of $15.10. The company has a 50 day moving average price of $11.13 and a 200 day moving average price of $9.42.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on IMMX shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Immix Biopharma in a research report on Thursday, October 15th. Morgan Stanley reissued an "overweight" rating on shares of Immix Biopharma in a research note on Tuesday, October 20th. HC Wainwright lifted their target price on Immix Biopharma from $20.00 to $25.00 and gave the stock a "buy" rating in a report on Monday, August 10th. Citigroup reaffirmed a "market outperform" rating on shares of Immix Biopharma in a research report on Wednesday, September 30th. Finally, Needham & Company LLC upped their target price on Immix Biopharma from $21.00 to $30.00 and gave the company a "buy" rating in a report on Tuesday, September 29th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Immix Biopharma currently has an average rating of "Moderate Buy" and a consensus price target of $23.86.

Immix Biopharma Company Profile

Immix Biopharma, Inc is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with difficult-to-treat cancers and other serious diseases. The company's research and development activities are centered on engineered immune-cell treatments intended to target malignant cells.

Its lead product candidate is NXC-201, an investigational autologous chimeric antigen receptor T-cell (CAR-T) therapy designed to target B-cell maturation antigen (BCMA). NXC-201 is being evaluated in clinical studies for relapsed or refractory multiple myeloma and relapsed or refractory AL amyloidosis, a rare blood disorder in which abnormal plasma cells produce misfolded proteins.

Immix Biopharma was founded in 2012 and is headquartered in Los Angeles, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.